

12 March 2026

Osteopore secures distribution rights for injectable regenerative bone filler

Australian-Singaporean regenerative medicine company **Osteopore Limited** (ASX: **OSX**; **Osteopore** or **Company**) – a global leader in 3D-printed biomimetic and bioresorbable implants – would like to provide clarification details relating to its non-exclusive distribution agreement with the Biomedical division of dsm-firmenich for its injectable regenerative bone filler in Southeast Asia (SEA). dsm-firmenich a publicly listed company on the Euronext Amsterdam (AMS: DSFIR) with a market capitalisation of approximately EUR 15 billion.

The nominal fee referred to in the original announcement is not material to Osteopore and represents approximately 1% of the Company's total assets at the end of FY25.

The quantum of the annual minimum order quantities is estimated to represent less than ~1% of the total market opportunity in SEA. This estimate was derived using available market data as a guide to the total market opportunity, i.e. indicating that the SEA region's share of the Asia Pacific orthobiologics and bone graft substitutes market is approximately ~AUD 94.6 to AUD 284M (10-30%).

With reference to the Company's revenue in FY25, successful commercialisation and achievement of the minimum order quantities would result in meaningful revenue contributions to the Company.

Subject to product registrations and effective commercialisation, the product has the potential to become a material revenue stream for Osteopore.



ENDS

This announcement has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Dr Yujing Lim

Chief Executive Officer

Osteopore Limited

E: lim_yujing@osteopore.com

Mark Leong

Executive Chairman

Osteopore Limited

E: mark_leong@osteopore.com

For personal use only



About Osteopore Limited

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

Forward-Looking Statements

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement.

You are cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements in this announcement reflect views held only as at the date of this announcement. This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.

